A European-Multicenter Network for the Implementation of Artificial Intelligence to Manage Complexity and Comorbidities of Atrial Fibrillation Patients: The ARISTOTELES Consortium

Atrial fibrillation (AF) is the most common arrhythmia worldwide, contributing significantly to morbidity, healthcare costs, and resource utilization. Patients with AF face a higher mortality and morbidity from stroke, heart failure, dementia, and hospitalizations. Oral anticoagulants (OACs) are the cornerstone of AF management, as they substantially reduce the risk of stroke and mortality. Nevertheless, some residual risk still remains despite anticoagulation, with most AF-related mortality linked to cardiovascular causes and comorbidities rather than stroke alone.